Table 2. Multivariate analysis.

	RR (95% CI) for R>D*	P-value
Overall survival
Children (2-<10)	0.85 (0.68-1.06)	0.15
Adolescents (10-<20)	1.04 (0.90-1.21)	0.58
Adults (20+)	1.06 (0.98-1.14)	0.14
Leukemia-free survival
Children (2-<10)	0.83 (0.67-1.04)	0.10
Adolescents (10-<20)	1.03 (0.90-1.20)	0.65
Adults (20+)	1.03 (0.96-1.10)	0.48
Non-relapse mortality
Children (2-<10)	0.90 (0.61-1.31)	0.58
Adolescents (10-<20)	1.11 (0.90-1.37)	0.34
Adults (20+)	1.03 (0.95-1.12)	0.48
Relapse
Children (2-<10)	0.85 (0.65-1.11)	0.23
Adolescents (10-<20)	1.02 (0.83-1.24)	0.87
Adults (20+)	1.04 (0.92-1.17)	0.58
Acute GVHD II-IV
Children (2-<10)	0.68 (0.54-0.87)	0.002
Adolescents (10-<20)	0.94 (0.81-1.11)	0.50
Adults (20+)	0.97 (0.89-1.05)	0.38
Acute GVHD III-IV
Children (2-<10)	0.89 (0.60-1.32)	0.56
Adolescents (10-<20)	0.86 (0.66-1.12)	0.25
Adults (20+)	0.96 (0.85-1.08)	0.46
Chronic GVHD
Children (2-<10)	0.51 (0.34-0.76)	0.001
Adolescents (10-<20)	0.68 (0.56-0.83)	0.0001
Adults (20+)	0.99 (0.91-1.08)	0.83

^*D>R RR 1.0

See text for listing of significant clinical co-variates. Stratified for significant non-proportional covariates